Biomea Fusion, Inc. (BMEA)

Market Cap	227.58M
Revenue (ttm)	n/a
Net Income (ttm)	-144.01M
Shares Out	36.24M
EPS (ttm)	-4.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	542,822
Open	6.51
Previous Close	6.42
Day's Range	6.04 - 6.55
52-Week Range	3.61 - 22.74
Beta	-0.43
Analysts	Buy
Price Target	37.25 (+493.15%)
Earnings Date	Oct 29, 2024

About BMEA

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 16, 2021
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: BMEA
• Website: https://biomeafusion.com

Analyst Forecast

According to 13 analysts, the average rating for BMEA stock is "Buy." The 12-month stock price forecast is $37.25, which is an increase of 493.15% from the latest price.

Price Target

$37.25

(493.15% upside)

Analyst Consensus: Buy